| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial
|
Zhao, C.
|
|
|
30 |
4 |
p. 637-643
|
artikel
|
| 2 |
Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia
|
Ruppert, A.S.
|
|
|
30 |
4 |
p. 542-550
|
artikel
|
| 3 |
Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics
|
Huemer, F.
|
|
|
30 |
4 |
p. 652-653
|
artikel
|
| 4 |
Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies
|
Abar, L.
|
|
|
30 |
4 |
p. 528-541
|
artikel
|
| 5 |
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
|
Garcia-Sanz, R.
|
|
|
30 |
4 |
p. 612-620
|
artikel
|
| 6 |
Chemotherapy-free treatments: are we ready for prime time?
|
Lorusso, D.
|
|
|
30 |
4 |
p. 497-498
|
artikel
|
| 7 |
Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials
|
Fontana, E.
|
|
|
30 |
4 |
p. 520-527
|
artikel
|
| 8 |
Editorial board
|
|
|
|
30 |
4 |
p. ii-iii
|
artikel
|
| 9 |
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial
|
Delaloge, S.
|
|
|
30 |
4 |
p. 567-574
|
artikel
|
| 10 |
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
|
Hamid, O.
|
|
|
30 |
4 |
p. 582-588
|
artikel
|
| 11 |
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA) †
|
Ghesquieres, H.
|
|
|
30 |
4 |
p. 621-628
|
artikel
|
| 12 |
Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer
|
Wiesweg, M.
|
|
|
30 |
4 |
p. 655-657
|
artikel
|
| 13 |
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
|
Stein, J.E.
|
|
|
30 |
4 |
p. 589-596
|
artikel
|
| 14 |
Meeting report from the joint IARC–NCI international cancer seminar series: a focus on colorectal cancer
|
Gunter, M.J.
|
|
|
30 |
4 |
p. 510-519
|
artikel
|
| 15 |
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
|
Bi, Y.
|
|
|
30 |
4 |
p. 644-651
|
artikel
|
| 16 |
Of mice and men: lost in translation
|
Groisberg, R.
|
|
|
30 |
4 |
p. 499-500
|
artikel
|
| 17 |
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
|
Robson, M.E.
|
|
|
30 |
4 |
p. 558-566
|
artikel
|
| 18 |
On the need to adjust for multiplicity in confirmatory clinical trials with master protocols
|
Stallard, N.
|
|
|
30 |
4 |
p. 506-509
|
artikel
|
| 19 |
On the underreporting of health-related quality of life and regulatory approval
|
Bhamidipati, D.
|
|
|
30 |
4 |
p. 657-658
|
artikel
|
| 20 |
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
|
Liu, J.F.
|
|
|
30 |
4 |
p. 551-557
|
artikel
|
| 21 |
Reply to the letter to the editor ‘On the underreporting of health-related quality of life and regulatory approval’ by Bhamidipati et al.
|
Di Maio, M.
|
|
|
30 |
4 |
p. 658-659
|
artikel
|
| 22 |
Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma
|
Rasmussen, J.H.
|
|
|
30 |
4 |
p. 629-636
|
artikel
|
| 23 |
Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment
|
Conforti, F.
|
|
|
30 |
4 |
p. 653-655
|
artikel
|
| 24 |
Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment
|
Weibring, K.
|
|
|
30 |
4 |
p. 604-611
|
artikel
|
| 25 |
Table of Contents
|
|
|
|
30 |
4 |
p. iv-vi
|
artikel
|
| 26 |
Targeting the MAPK pathway in advanced BRAF wild-type melanoma
|
Massa, R.C.
|
|
|
30 |
4 |
p. 503-505
|
artikel
|
| 27 |
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
|
Barroso-Sousa, R.
|
|
|
30 |
4 |
p. 575-581
|
artikel
|
| 28 |
Treatment in metastatic melanoma—time to re-think
|
Schadendorf, D.
|
|
|
30 |
4 |
p. 501-503
|
artikel
|
| 29 |
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
|
Li, B.T.
|
|
|
30 |
4 |
p. 597-603
|
artikel
|
| 30 |
Value assessment frameworks in oncology: championing concordance through shared standards
|
Bertagnolli, M.
|
|
|
30 |
4 |
p. 505-506
|
artikel
|
Tijdschrift beschrijving